Patents by Inventor Martin John Glennie
Martin John Glennie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11780929Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: GrantFiled: April 20, 2021Date of Patent: October 10, 2023Assignee: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20220213207Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: ApplicationFiled: April 20, 2021Publication date: July 7, 2022Applicant: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20210317222Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: ApplicationFiled: April 20, 2021Publication date: October 14, 2021Applicant: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Patent number: 11001638Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: GrantFiled: November 4, 2016Date of Patent: May 11, 2021Assignee: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20200247898Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: ApplicationFiled: February 5, 2020Publication date: August 6, 2020Inventors: Martin John GLENNIE, Alison Louise TUTT, Aymen AL-SHARNKHANI
-
Publication number: 20200017594Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: ApplicationFiled: November 4, 2016Publication date: January 16, 2020Applicant: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20190169306Abstract: The disclosure relates to a method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell; and an immunostimulatory agent arranged to stimulate effector lymphocytes, such as NK and/or T cells. Additionally, an anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject. The disclosure also relates to a method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell; and an immunostimulatory agent arranged to stimulate NK and/or T-cell activation. Additionally, an anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.Type: ApplicationFiled: July 28, 2017Publication date: June 6, 2019Inventors: Martin John Glennie, Aymen Al-Shamkhani, Mark Steven Cragg, Sean Hua Lim
-
Publication number: 20180327504Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: ApplicationFiled: November 4, 2016Publication date: November 15, 2018Applicant: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20180273631Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: ApplicationFiled: March 23, 2018Publication date: September 27, 2018Inventors: Martin John GLENNIE, Alison Louise TUTT, Aymen AL-SHAMKHANI
-
Patent number: 9926374Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: GrantFiled: December 18, 2015Date of Patent: March 27, 2018Assignee: UNIVERSITY OF SOUTHAMPTONInventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Publication number: 20160215056Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: ApplicationFiled: December 18, 2015Publication date: July 28, 2016Inventors: Martin John GLENNIE, Alison Louise TUTT, Aymen AL-SHARNKHANI
-
Patent number: 9248183Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: GrantFiled: May 30, 2013Date of Patent: February 2, 2016Assignee: University of SouthamptonInventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Publication number: 20130336976Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: ApplicationFiled: May 30, 2013Publication date: December 19, 2013Inventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Patent number: 8481029Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: GrantFiled: October 18, 2007Date of Patent: July 9, 2013Assignee: University of SouthamptonInventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Publication number: 20110033449Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: ApplicationFiled: October 18, 2007Publication date: February 10, 2011Inventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani